These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38806289)

  • 1. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.
    Cao C; Fang Y; Jiang F; Jin Q; Jin T; Huang S; Hu Q; Chen Y; Piao Y; Hua Y; Feng X; Chen X
    Cancer Sci; 2024 Aug; 115(8):2729-2737. PubMed ID: 38806289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy.
    Guo LF; Rao MY; Yu YF; Lin Q; Wu SG
    BMC Cancer; 2024 Aug; 24(1):950. PubMed ID: 39095737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
    BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis.
    Zhi-Qiang W; Qi M; Ji-Bin L; Rui Y; You-Ping L; Rui S; Guang-Yuan H; Ming-Yuan C; Yi-Jun H
    BMC Cancer; 2019 Nov; 19(1):1122. PubMed ID: 31744469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
    Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
    BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
    Gao M; Yuan T; Zhang F
    J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma.
    Yu YF; Zhou P; Zhou R; Lin Q; Wu SG
    Ann Med; 2024 Dec; 56(1):2383959. PubMed ID: 39086168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
    Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
    Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
    Zhang S; Huang X; Zhou L; Lin S
    Medicine (Baltimore); 2018 Sep; 97(38):e12503. PubMed ID: 30235761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
    Zong JF; Liang QD; Lu QJ; Liu YH; Xu HC; Chen BJ; Guo QJ; Xu Y; Hu CR; Pan JJ; Lin SJ
    BMC Cancer; 2021 Nov; 21(1):1274. PubMed ID: 34823489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma].
    Liu KQ; Jin F; Jiang H; Wu WL; Li YY; Long JH; Luo XL; Gong XY; Chen XX; Liu LN; Gan JY; Zhou JJ
    Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):133-138. PubMed ID: 32135648
    [No Abstract]   [Full Text] [Related]  

  • 15. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
    Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L
    BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locally advanced nasopharyngeal carcinoma in adolescents treated with tomotherapy: Experience at King Faisal Specialist Hospital and Research Centre.
    Aldakheel A; Aldehaim M; Alwhaid MS; Alhabib R; Anwar MS; Alzayed B; Shehzad K; Ghebeh H; Al-Rajhi N
    Ann Saudi Med; 2024; 44(3):153-160. PubMed ID: 38853474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.